• +1 700 888 1234

  • Effingerstrasse 40 3008 Bern Switzerland

LUCE HIGHLIGHTS – 2018

Lung Cancer Europe (LuCE) marked the World Cancer Day by launching the European Call to Action Campaign. The call highlights […]

LUCE TO ACT AS A RELEVANT STAKEHOLDER IN THE BATTLE AGAINST LUNG CANCER

Lung Cancer Europe was present at the European Cancer Forum held in Brussels. Brussels, 4 December 2018 MSD, in collaboration with […]

LUCE REPORT 2018: CHALLENGES IN LUNG CANCER CLINICAL TRIALS

Welcome to the 3rd edition of the LuCE Report. This report is an annual initiative led by lung cancer patient […]

HAPPY ADVOCATE

“I am very happy to be an advocate these days because so many good things have started to happen in […]

28TH NOVEMBER: CURRENT CHALLENGES IN CLINICAL TRIALS

Lung Cancer Europe will hold an event on 28th November at the EU Parliament to highlight the current challenges in clinical […]

NOVEMBER IS LUNG CANCER AWARENESS MONTH

According to Globocan 2018, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total […]

BEING HEARD OVER THE NOISE

LuCE president, Stefania Vallone provided an insight analysis on “Being heard over the noise: The patient viewpoint” during #ESMO2018. She […]

LUCE STAND AT ESMO 2018

We invite all interested ESMO members to visit us @LuCE booth located in the society village at ESMO 2018 in […]

NEW GLOBOCAN STATISTICS PLACED LUNG CANCER AS THE MOST FREQUENT CANCER AND THE LEADING CAUSE OF CANCER DEATH AMONG MALES

According to tthe new statistics, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6 % of […]

#WCLC2018 CONCLUSIONS – STRATEGIES TO MAXIMIZE THE CLINICAL BENEFIT OF EGFR TKIS IN ADVANCED NSCLC

During the congress, one of the topics covered focused on the importance of EGFR TKIs in Advanced NSCLC. Apply expert […]